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related to the additive or synergic virulence of a
mixed flora.
The mortality rate of invasive GBS infections in
non-pregnant adults varies greatly, ranging from
8% [16] to 32% [2]. Factors associated with a poor
outcome among patients with invasive GBS infec-
tions have been described previously [14,17].
However, such information is scant with respect
to GBS soft tissue infections. The present study
found that critical illness at admission and cuta-
neous ulceration were indicative of a poor clinical
outcome in GBS soft tissue infections, with a
fatality rate of 7%.
In conclusion, invasive soft tissue infections
caused by GBS are not uncommon in non-preg-
nant adults, especially the elderly and patients
with diabetes mellitus, and can result in substan-
tial morbidity and mortality. Prolonged duration
of antimicrobial therapy and early surgical inter-
ventions are indicated for life-threatening infec-
tions.
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ABSTRACT
The antimicrobial susceptibilities of 338 clinical
Streptococcus agalactiae isolates from two geo-
graphical regions in Germany were determined
by agar dilution. All isolates were susceptible to
penicillin, cefotaxime and vancomycin. The over-
all frequencies of erythromycin and clindamycin
resistance were 11% and 4.7%, respectively.
Determination of resistance phenotypes among
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the 37 erythromycin-resistant isolates revealed
constitutive and inducible MLSB resistance in
40.6% and 37.8% of isolates, respectively, and
susceptibility to clindamycin in 21.6% of isolates.
Only 14.3% of isolates with inducible MLSB
resistance were identified as clindamycin-resist-
ant by determination of clindamycin MICs.
Pulsed-field gel electrophoresis suggested a clonal
distribution pattern among the erythromycin-
resistant isolates.
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Streptococcus agalactiae (group B Streptococcus; GBS)
remains an important cause of neonatal morbidity
and mortality, and of serious disease in adults,
including sepsis, pneumonia, and soft tissue and
urinary tract infections [1,2]. Penicillin and ampi-
cillin are the drugs of choice for prophylaxis and
treatment of GBS disease. Erythromycin and clin-
damycin are the recommended second-line drugs,
particularly in cases of penicillin allergy [2]. How-
ever, recent reports of increasing resistance to
erythromycin and clindamycin among GBS iso-
lates have raised concerns about their use as
alternative agents [3–6]. Furthermore, decreased
susceptibility to penicillin among GBS isolates has
been reported sporadically [7]. The present study
was performed to determine the antimicrobial
susceptibilities, particularly to erythromycin and
clindamycin, of GBS isolates from two geograph-
ical regions of Germany. Erythromycin-resistant
isolates were analysed further by double-disk
diffusion tests to elucidate the underlying resist-
ance mechanisms, and were also typed by pulsed-
field gel electrophoresis (PFGE).
In total, 338 GBS isolates were collected con-
secutively from January until August 2001 in the
clinical microbiology laboratories of the Univer-
sity Hospital, University of Heidelberg (south-
west Germany), University Hospital Benjamin
Franklin, Charite´ Universita¨tsmedizin Berlin, and
Vivantes Kliniken, Berlin (north-east Germany).
Isolates were obtained from vaginal or rectal
exudates of pregnant women (n = 171), the ear,
nose or gastric fluid of neonates (n = 22), urine,
ejaculate or urethral samples (n = 55), skin (n = 7)
and respiratory specimens (n = 8). These isolates
were considered non-invasive (n = 263). In addi-
tion, 75 invasive isolates were obtained from
central venous catheters (n = 2), blood culture
(n = 6), cerebrospinal fluid and blood culture of a
neonate (n = 1), drain exudates (n = 3) and severe
soft tissue infections (n = 63). Susceptibility testing
for penicillin G, erythromycin, clindamycin, cefo-
Table 1. Antimicrobial susceptibility
profiles of group B streptococcal iso-
lates collected in 2001 from two geo-
graphical regions of Germany
Geographical
region (n)
Antimicrobial
agent
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
MIC range
(mg ⁄L)
Susceptible
(%)
Resistant
(%)
Heidelberg (202) Erythromycin 0.125 4 0.06 to ‡ 16 87.7 12.3
Clindamycin 0.125 0.125 0.06 to ‡ 16 94.6 5.4
Penicillin 0.03 0.03 £ 0.007–0.125 100 0
Cefotaxime 0.03 0.03 £ 0.015–0.03 100 0
Vancomycin 0.25 0.5 0.25–0.5 100 0
Ciprofloxacin 0.5 1 0.25 to ‡ 16 99.5 0.5
Berlin (136) Erythromycin 0.25 0.25 0.06 to ‡ 16 90.4 9.6
Clindamycin 0.06 0.06 0.06 to ‡ 16 96.3 3
Penicillin 0.03 0.03 £ 0.007–0.06 100 0
Cefotaxime 0.03 0.03 £ 0.015–0.03 100 0
Vancomycin 0.25 0.25 0.25–0.5 100 0
Ciprofloxacin 0.5 1 0.25–2 100 0
Total (338) Erythromycin 0.125 4 0.06 to ‡ 16 89 11
Clindamycin 0.125 0.125 0.06 to ‡ 16 95 4.7
Penicillin 0.03 0.03 £ 0.007–0.125 100 0
Cefotaxime 0.03 0.03 £ 0.015–0.03 100 0
Vancomycin 0.25 0.5 0.25–0.5 100 0
Ciprofloxacin 0.5 1 0.25 to ‡ 16 99.7 0.3
Table 2. Distribution of clindamycin MICs among isolates
with different resistance phenotypes
Resistance
type (n)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
MIC
range
(mg ⁄L)
Accuracy of MIC
results for detection of
resistance to clindamycin
Constitutive
MLSB resistance (15)
16 16 1 to ‡ 16 15 ⁄ 15 (100%)
Inducible
MLSB resistance (14)
0.125 0. 25 0.06–0.5 2 ⁄ 14 (14.3%)
M-type (8) 0.125 0.125 0.06–0.125 8 ⁄ 8 (100%)
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taxime, ciprofloxacin and vancomycin was per-
formed by agar dilution using Mueller–Hinton
agar containing sheep blood 5% v ⁄ v [8]. NCCLS
interpretation criteria were used for all agents,
except ciprofloxacin, for which no NCCLS break-
points are available. However, ciprofloxacin
is often prescribed by general practitioners in
Germany and was therefore included in this study
with the interpretation criteria of the Deutsches
Institut fu¨r Normung (DIN) [9]. Double-disk dif-
fusion tests were performed as described previ-
ously [10,11]. PFGE analysis of chromosomal DNA
was performed following restriction with SmaI
[12]. Restriction patterns were analysed according
to interpretation criteria for bacterial strain typing
[13]. Isolates displaying up to three band differ-
ences were assigned to one PFGE type.
All isolates were susceptible to penicillin, cefo-
taxime and vancomycin. The MIC50 and MIC90
values of penicillin were 0.03 mg ⁄L (Table 1).
Resistance to erythromycin was detected in 37
(11%) isolates. The resistance rate was slightly
higher in isolates from Heidelberg compared to
Berlin (12.3 vs. 9.6%; p 0.5; chi-square test). The
frequency of erythromycin resistance was 12.2%
among the non-invasive isolates and 6.7% among
the invasive isolates (p 0.18). Sixteen (4.7%) iso-
lates were resistant, and one (0.3%) showed
intermediate resistance to clindamycin. One iso-
late was resistant to clindamycin (MIC 1 mg ⁄L),
but susceptible to erythromycin (MIC 0.25 mg ⁄L).
One isolate from a diabetic foot ulcer was resist-
ant to ciprofloxacin (MIC ‡ 16 mg ⁄L).
Determination of the resistance phenotypes
revealed constitutive MLSB resistance in 15
(40.6%) and inducible MLSB resistance in 14
(37.8%) of the erythromycin-resistant isolates
(n = 37). Eight (21.6%) isolates were resistant to
erythromycin, but susceptible to clindamycin (M-
type), suggesting the presence of an erythromycin
efflux mechanism. The prevalence of M-type was
higher among invasive isolates (40%) than among
non-invasive isolates (18.7%), although the dif-
ference was not statistically significant (p 0.28).
MIC values of clindamycin correlated to some
extent with the resistance phenotypes. Constitu-
tively MLSB-resistant isolates had higher MICs
than isolates possessing inducible MLSB resist-
ance or M-type (Table 2). Notably, only two of 14
isolates with inducible MLSB resistance were
identified correctly as resistant to clindamycin
by clindamycin MIC determinations. All M-type
isolates revealed MIC results concordant with
susceptibility to clindamycin.
PFGE analysis revealed 18 different patterns
among the erythromycin-resistant isolates (data
not shown). Two isolates were non-typeable.
Twelve PFGE types were associated with one
isolate each. Patterns M, C and D were displayed
by two, three and four isolates, respectively.
Pattern E was found in 12 isolates retrieved from
both geographical regions and accounted for
34.3% of the typeable isolates. All type E isolates
displayed the MLSB resistance phenotype. These
results suggest a clonal distribution pattern
among the erythromycin-resistant isolates in Ger-
many. Confirmation of these data by further
genotyping methods, e.g., multilocus sequence
typing [19], would help to further elucidate the
genetic relatedness among erythromycin-resistant
isolates and facilitate the inter-laboratory com-
parison of genotyping data.
In conclusion, all GBS isolates included in this
study were susceptible to penicillin, cefotaxime
and vancomycin. These results agree with recent
data from other countries [4,6,14–17], and confirm
that use of penicillin as a first-choice drug for
prophylaxis and therapy of GBS infections in
Germany is appropriate. A high rate of erythro-
mycin resistance (11%) was found among the
GBS isolates studied. These results agree with
data from the Freiburg area (south-west Ger-
many), which showed a resistance rate of 10% in
1999 [16], but differ significantly from the 2%
erythromycin resistance rate reported by another
German group in 1997 [18]. This discrepancy may
be related to the different isolate collection peri-
ods. Other studies have shown a drastic increase
in the prevalence of erythromycin resistance in
GBS during the 1990s [16]. Thus, erythromycin
should no longer be relied upon as an alternative
agent for prophylaxis and therapy of GBS infec-
tions in Germany without susceptibility testing.
Since the determination of clindamycin MICs is
not appropriate for the detection of inducible
MLSB resistance, the use of the double-disk
diffusion test is strongly recommended.
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ABSTRACT
In total, 408 staphylococcal isolates were tested
for inducible clindamycin resistance (ICR) by
the disk-diffusion induction test (D-test). ICR
was detected in 5.7% of 105 methicillin-resistant
Staphylococcus aureus (MRSA) isolates, 3.6% of
111 methicillin-susceptible S. aureus isolates,
30.8% of 94 methicillin-resistant coagulase-negat-
ive staphylococcal (CoNS) isolates, and 11.2% of
98 methicillin-sensitive CoNS isolates. All MRSA
isolates that were erythromycin-resistant and
clindamycin-susceptible were positive by the
D-test. The same results were obtained with an
azithromycin instead of an erythromycin disk.
All isolates were susceptible to quinupristin–
dalfopristin. The cost–benefit of the D-test
should be evaluated locally after determining
the incidence of the different resistance pheno-
types.
Keywords Clindamycin resistance, coagulase-negat-
ive staphylococci, disk-diffusion induction test, D-test,
macrolide resistance, Staphylococcus aureus
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